Clinical Trial Update: Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial funded by the National Cancer Institute evaluated the proteasome inhibitor bortezomib for hepatocellular carcinoma (liver can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: COMPLETED